Timing controlled in-situ cross-linking of halyuronic acid during injection
Systems and methods are disclosed for cosmetic augmentation by forming a biocompatible cross-linked polymer having a multi-phase mixture with a time release catalyst; injecting the mixture into a patient as a viscous fluid; after injection, activating the catalyst to cross-link the polymer after a predetermined period after injection into a patient; and augmenting soft tissue with the biocompatible cross-linked polymer.
1. A method for cosmetic augmentation, comprising:
modeling a 3D model of a human body and continuously updating a current shape of breast or butt from the 3D model to fit to a desired shape;
forming a biocompatible cross-linked polymer having a multi-phase mixture with a time activated catalyst;
injecting the mixture into a patient as a homogeneous fluid;
after injection, activating the catalyst to cross-link the polymer after a predetermined period after injection into a patient; and
augmenting soft tissue with the biocompatible cross-linked polymer.
2. The method of claim 1 , comprising providing a predetermined controlled release of selected pharmaceutical substance to modulate soft tissue response to the polymer.
3. The method of claim 1 , comprising cross-linking the polymer in a shell inside the patient.
4. The method of claim 1 , wherein the polymer comprises one of: collagens, hyaluronic acids, celluloses, proteins, saccharides.
5. The method of claim 1 , wherein the polymer comprises an extracellular matrix of a biological system.
6. The method of claim 1 , comprising using cross linkers and forming homo-polymers or to form copolymers by crosslinking with other polymer species.
7. The method of claim 1 , comprising adding a substance to the composition for biocompatibility.
8. The method of claim 1 , comprising controlling drug releases at predetermined timing in anticipation of an onset of a negative physiological event in response to invading foreign bodies.
9. The method of claim 1 , comprising fast releasing the composition.
10. The method of claim 1 , comprising adding anesthetics, lidocaine or compound to reduce or eliminate acute inflammatory reactions to the pharmaceutical substance.
11. The method of claim 1 , comprising adding one or more compositions selected from the group consisting of steroids, corticosteroids, dexamethasone, triamcinolone.
12. The method of claim 1 , comprising providing a slow release substance to the pharmaceutical substance.
13. The method of claim 1 , comprising providing an antiproliferative compound.
14. The method of claim 1 , wherein the substance comprises paclitaxel, serolimas.
15. The method of claim 1 , comprising controlling the scar formation process around a foreign body including capsular formation.
16. The method of claim 1 , comprising providing a medium release to the pharmaceutical substance.
17. The method of claim 1 , comprising optimizing degradation profile of the composition.
18. The method of claim 1 , comprising minimizing migration of the composition.
19. The method of claim 1 , comprising controlling an average molecular weight (Mn) and the polydispersity index.
20. The method of claim 1 , comprising characterizing a target tissue, and maintaining a consistency of the composition in particle size and population densities.
21. The method of claim 1 , comprising co-cross-linking glycosaminoglycan chemically with at least one other polymer including hyaluronan or hylan.
22. The method of claim 1 , comprising adding a biodegradable surfactant or plasticizer to reduce surface tension of material as it is injected into a patient through a small diameter needle.
23. The method of claim 1 , comprising injecting with a mechanical pump the biocompatible crosslinked polymer under soft tissue in a minimally invasive manner.
24. A method for cosmetic augmentation, comprising:
modeling a 3D model of a human body and continuously updating a current shape of breast or butt from the 3D model to fit to a desired shape,
forming a biocompatible cross-linked polymer having a multi-phase mixture with a predetermined controlled release of selected pharmaceutical substance to modulate soft tissue response to the polymer;
injecting the mixture into a patient and during or after injection, cross-linking the polymer in the patient;
filling a semi-permeable shell with the pharmaceutical substance; and
augmenting soft tissue with the biocompatible cross-linked polymer.